Patent US4590071A successfully refreshed from Google Patents.
US4590071A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Human melanoma specific immunotoxins
Assignee: Xoma Royalty Corp
•
Filing: 1984-09-25
•
Granted: 1986-05-20
•
Expires: 2004-09-25
Abstract
Abstract Conjugates of monoclonal antibodies specific to human melanoma and the A chain of a toxic lectin such as ricin or an equivalent ribosomal inhibiting protein. The conjugate is synthesized by a novel process employing anti-toxic lectin B chain antibodies to remove lectin B chain impurities and provide a highly purified conjugate that is non-toxic to cells other than melanoma. The conjugates are used to treat human melanoma. The hybridomas XMMME-001 and XMMME-002 were deposited with the American Type Culture Collection (A.T.C.C.) on Mar. 26, 1985, and given A.T.C.C. Accession Nos. HB8759 and HB8760, respectively.
Inventors
- 👤 Patrick J. Scannon
- 👤 Lynn E. Spitler
- 👤 Howard M. Lee
- 👤 Russell T. Kawahata
- 👤 Ronald P. Mischak
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 08:53
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; C07K16/3053; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6811; A61K47/6817; A61K47/6819; A61K47/6825; A61K47/6827; A61K47/6835; A61K47/6851; A61K47/6865; A61K38/00
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
33 words
A cytotoxic conjugate, comprising a lectin A chain purified with anti-lectin B chain antibodies bound to a monoclonal antibody that binds substantially only human melanoma associated antigen to about 240 kD/480 kD m.w.
Claim 2
Dependent Claim
33 words
A cytotoxic conjugate, comprising a lectin A chain purified with anti-lectin B chain antibodies bound to a monoclonal antibody that binds substantially only human melanoma associated antigen to about 240 kD/480 kD m.w.
Claim 3
Dependent Claim
22 words
The conjugate as claimed in claim 1, wherein the monoclonal antibody is that produced by hybridoma XMMME-001 having A.T.C.C. Accession No. HB8759.
Claim 4
Dependent Claim
22 words
The conjugate as claimed in claim 1, wherein the monoclonal antibody is that produced by hybridoma XMMME-002 having A.T.C.C. Accession No. HB8760.
Claim 5
Dependent Claim
22 words
The conjugate as claimed in claim 1, wherein the lectin A chain is abrin A chain purified with anti-abrin B chain antibodies.
Claim 6
Dependent Claim
78 words
A cytotoxic therapeutic cocktail comprising a first conjugate of a lectin A chain purified with anti-lectin B chain antibodies bound to a monoclonal antibody that binds substantially only human melanoma associated antigen of about 240 kD/480 kD m.w. and a second conjugate of a lectin A chain purified with anti-lectin B chain antibodies bound to a different monoclonal antibody that binds substantially only human melanoma associated antigen of about 240 kD/480 kD m.w. than in the first conjugate.
Claim 7
Dependent Claim
78 words
A cytotoxic therapeutic cocktail comprising a first conjugate of a lectin A chain purified with anti-lectin B chain antibodies bound to a monoclonal antibody that binds substantially only human melanoma associated antigen of about 240 kD/480 kD m.w. and a second conjugate of a lectin A chain purified with anti-lectin B chain antibodies bound to a different monoclonal antibody that binds substantially only human melanoma associated antigen of about 240 kD/480 kD m.w. than in the first conjugate.
Claim 8
Dependent Claim
26 words
The cocktail as claimed in claim 5, wherein the monoclonal antibody of the first conjugate is that produced by hybridoma XMMME-001 having A.T.C.C. Accession No. HB8759.
Claim 9
Dependent Claim
26 words
The cocktail as claimed in claim 5, wherein the monoclonal antibody of the first conjugate is that produced by hybridoma XMMME-002 having A.T.C.C. Accession No. HB8760.
Claim 10
Dependent Claim
26 words
The cocktail as claimed in claim 6, wherein the monoclonal antibody of the second conjugate is that produced by hybridoma XMMME-002 having A.T.C.C. Accession No. HB8760.
Claim 11
Dependent Claim
28 words
The cocktail as claimed in claim 5, wherein the lectin A chain of the first and second conjugates is abrin A chain purified with anti-abrin B chain antibodies.
Claim 12
Dependent Claim
45 words
The cocktail as claimed in claim 5, wherein the lectin A chain of the first conjugate is ricin A chain purified with anti-ricin B chain antibodies and the lectin A chain of the second conjugate is abrin A chain purified with anti-abrin B chain antibodies.
Claim 13
Dependent Claim
27 words
A method for the treatment of human melanoma cells, comprising administering a therapeutic dose of the conjugate claimed in claim 1 to a human melanoma cell host.
Claim 14
Dependent Claim
27 words
A method for the treatment of human melanoma cells, comprising administering a therapeutic dose of the cocktail claimed in claim 5 to a human melanoma cell host.
Claim 15
Dependent Claim
34 words
A method for the treatment of human melanoma cells, comprising administering approximately 0.01 to 20.0 milligrams of the conjugate claimed in claim 1 to a melanoma cell host per kilogram of host body weight.
Claim 16
Dependent Claim
45 words
A method for the treatment of human melanoma cells, comprising administering the clocktail claimed in claim 5 to a melanoma cell host, wherein the total dose of all conjugates is in the approximate range of 0.01 to 20.0 milligrams per kilogram of host body weight.
Claim 17
Dependent Claim
34 words
Antibodies having substantially the same specificity as antibodies produced by hybridoma XMMME-001 having A.T.C.C. Accession No. HB8759 which produces antibodies that bind substantially only human melanoma associated antigens of about 240 kD/480 kD m.w.
Claim 18
Dependent Claim
34 words
Antibodies having substantially the same specificity as antibodies produced by hybridoma XMMME-001 having A.T.C.C. Accession No. HB8759 which produces antibodies that bind substantially only human melanoma associated antigens of about 240 kD/480 kD m.w.
Claim 19
Dependent Claim
34 words
Antibodies having substantially the same specificity as antibodies produced by hybridoma XMMME-002 having A.T.C.C. Accession No. HB8760 which produces antibodies that bind substantially only human melanoma associated antigens of about 240 kD/480 kD m.w.
Claim 20
Dependent Claim
34 words
Antibodies having substantially the same specificity as antibodies produced by hybridoma XMMME-002 having A.T.C.C. Accession No. HB8760 which produces antibodies that bind substantially only human melanoma associated antigens of about 240 kD/480 kD m.w.
Claim 21
Dependent Claim
24 words
Hybridoma XMMME-001 having A.T.C.C. Accession No. HB8759 which produces antibodies that bind substantially only human melanoma associated antigens of about 240 kD/480 kD m.w.
Claim 22
Dependent Claim
24 words
Hybridoma XMMME-001 having A.T.C.C. Accession No. HB8759 which produces antibodies that bind substantially only human melanoma associated antigens of about 240 kD/480 kD m.w.
Claim 23
Dependent Claim
24 words
Hybridoma XMMME-002 having A.T.C.C. Accession No. HB8760 which produces antibodies that bind substantially only human melanoma associated antigens of about 240 kD/480 kD m.w.
Claim 24
Dependent Claim
24 words
Hybridoma XMMME-002 having A.T.C.C. Accession No. HB8760 which produces antibodies that bind substantially only human melanoma associated antigens of about 240 kD/480 kD m.w.
Claim 25
Dependent Claim
32 words
A cytotoxic conjugate, comprising ricin A chain purified with anti-ricin B chain antibodies bound to a monoclonal antibody that binds substantially only human melanoma associated antigen of about 240 kD/480 kD m.w.
Claim 26
Dependent Claim
32 words
A cytotoxic conjugate, comprising ricin A chain purified with anti-ricin B chain antibodies bound to a monoclonal antibody that binds substantially only human melanoma associated antigen of about 240 kD/480 kD m.w.
Claim 27
Dependent Claim
76 words
A cytotoxic therapeutic cocktail comprising a first conjugate of ricin A chain, purified with anti-ricin B chain antibodies, bound to a monoclonal antibody that binds substantially only human melanoma associated antigen of about 240 kD/480 kD m.w., and a second conjugate of ricin A chain, purified with anti-ricin B chain antibodies, bound to a different monoclonal antibody than in the first conjugate, that binds substantially only human melanoma associated antigen of about 240 kD/480 kD m.w.
Claim 28
Dependent Claim
76 words
A cytotoxic therapeutic cocktail comprising a first conjugate of ricin A chain, purified with anti-ricin B chain antibodies, bound to a monoclonal antibody that binds substantially only human melanoma associated antigen of about 240 kD/480 kD m.w., and a second conjugate of ricin A chain, purified with anti-ricin B chain antibodies, bound to a different monoclonal antibody than in the first conjugate, that binds substantially only human melanoma associated antigen of about 240 kD/480 kD m.w.
References Cited (Backward Citations)
US4172124A
Cited
US4340535A
Cited
US4450154A
Cited
FR2466252A2
Cited
US4427653A
Cited
US4414148A
Cited
US4474893A
Cited
WO1983004312A1
Cited
US4562160A
Cited
GB2142032A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-05-19 | 1989-11-18 | 1990-05-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-05-19 | 1993-11-18 | 1994-05-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-05-19 | 1997-11-18 | 1998-05-20 | $7700.00 | Window Closed / Lapsed |